adenine has been researched along with Lassitude in 12 studies
Excerpt | Relevance | Reference |
---|---|---|
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 9.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 5.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)." | 2.90 | Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019) |
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg." | 2.78 | Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 9 (75.00) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
Authors | Studies |
---|---|
Mayer, KH | 1 |
Gelman, M | 1 |
Holmes, J | 1 |
Kraft, J | 1 |
Melbourne, K | 1 |
Mimiaga, MJ | 1 |
Deering, KL | 1 |
Sundaram, M | 1 |
Harshaw, Q | 1 |
Trudeau, J | 1 |
Barrientos, JC | 4 |
Cramer, P | 1 |
Fraser, G | 1 |
Santucci-Silva, R | 1 |
Grosicki, S | 2 |
Dilhuydy, MS | 1 |
Janssens, A | 2 |
Loscertales, J | 1 |
Rule, S | 1 |
Goy, A | 1 |
Traina, S | 1 |
Chan, EKH | 1 |
Diels, J | 1 |
Sengupta, N | 1 |
Mahler, M | 1 |
Salman, M | 1 |
Howes, A | 1 |
Chanan-Khan, A | 1 |
Gribben, JG | 1 |
Bosch, F | 1 |
Cymbalista, F | 2 |
Geisler, CH | 1 |
Ghia, P | 3 |
Hillmen, P | 4 |
Moreno, C | 3 |
Stilgenbauer, S | 1 |
Chari, A | 1 |
Larson, S | 1 |
Holkova, B | 1 |
Cornell, RF | 1 |
Gasparetto, C | 1 |
Karanes, C | 1 |
Matous, JV | 1 |
Niesvizky, R | 1 |
Valent, J | 1 |
Lunning, M | 1 |
Usmani, SZ | 1 |
Anderson, LD | 1 |
Chang, L | 1 |
Lee, Y | 1 |
Pak, Y | 1 |
Salman, Z | 1 |
Graef, T | 1 |
Bilotti, E | 2 |
Chhabra, S | 1 |
Coutre, SE | 2 |
Byrd, JC | 3 |
Barr, PM | 3 |
Devereux, S | 3 |
Robak, T | 3 |
Kipps, TJ | 3 |
Schuh, A | 3 |
Furman, RR | 3 |
Burger, JA | 3 |
O'Dwyer, M | 2 |
Valentino, R | 1 |
Chang, S | 1 |
Dean, JP | 1 |
James, DF | 4 |
O'Brien, SM | 1 |
Ruane, PJ | 1 |
DeJesus, E | 1 |
Berger, D | 1 |
Markowitz, M | 1 |
Bredeek, UF | 1 |
Callebaut, C | 1 |
Zhong, L | 1 |
Ramanathan, S | 1 |
Rhee, MS | 1 |
Fordyce, MW | 1 |
Yale, K | 1 |
Brown, JR | 1 |
O'Brien, S | 2 |
Kay, NE | 1 |
Reddy, NM | 1 |
Coutre, S | 2 |
Tam, CS | 2 |
Mulligan, SP | 1 |
Jaeger, U | 1 |
Pocock, C | 1 |
Thornton, P | 1 |
Caligaris-Cappio, F | 1 |
Delgado, J | 1 |
Schuster, SJ | 1 |
Montillo, M | 1 |
de Vos, S | 2 |
Gill, D | 1 |
Bloor, A | 1 |
Dearden, C | 1 |
Jones, JJ | 1 |
Chu, AD | 1 |
Fardis, M | 1 |
McGreivy, J | 1 |
Clow, F | 2 |
Blum, KA | 1 |
Coleman, M | 2 |
Wierda, WG | 1 |
Jones, JA | 1 |
Zhao, W | 1 |
Heerema, NA | 1 |
Johnson, AJ | 1 |
Shaw, Y | 1 |
Zhou, C | 1 |
Tedeschi, A | 1 |
Owen, C | 1 |
Bairey, O | 1 |
Bartlett, NL | 1 |
Li, J | 1 |
Simpson, D | 1 |
McCarthy, H | 1 |
Quach, H | 1 |
Gaidano, G | 1 |
Maslyak, Z | 1 |
Stevens, DA | 1 |
Offner, F | 1 |
Mayer, J | 1 |
Hellmann, A | 1 |
Siddiqi, T | 1 |
Polliack, A | 1 |
Suri, D | 1 |
Cheng, M | 1 |
Styles, L | 1 |
Noy, A | 1 |
Thieblemont, C | 1 |
Martin, P | 1 |
Flowers, CR | 1 |
Morschhauser, F | 1 |
Collins, GP | 1 |
Ma, S | 1 |
Peles, S | 1 |
Smith, S | 1 |
Smith, A | 1 |
Munneke, B | 1 |
Dimery, I | 1 |
Beaupre, DM | 1 |
Chen, R | 1 |
KIRZON, MV | 1 |
ALLIK, TA | 1 |
SHESTAKOV, SV | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1[NCT03499483] | Phase 4 | 52 participants (Actual) | Interventional | 2019-01-24 | Completed | ||
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069] | Phase 2 | 199 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346] | Phase 3 | 232 participants (Actual) | Interventional | 2012-08-28 | Completed | ||
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487] | Phase 3 | 269 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370] | Phase 4 | 10 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947] | Phase 2 | 3 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470] | 92 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628] | Phase 2 | 63 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 42 |
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH | 199 |
A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 70 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
Intervention | (Number) |
---|---|
Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
Intervention | Participants (Number) |
---|---|
PCI-32765 | 116 |
Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 71 |
Relapsed/ Refractory | 75.3 |
Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 96.3 |
Relapsed/ Refractory | 73.6 |
Food- Effect | NA |
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 65.1 |
Ibrutinib (Arm B) | 67.7 |
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 4.1 |
Ibrutinib (Arm B) | 42.6 |
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 22.4 |
Ibrutinib (Arm B) | 87.7 |
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | NA |
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | 44.1 |
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) | |
---|---|---|
Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
Ibrutinib (Arm B) | 69.7 | 78.4 |
Ofatumumab (Arm A) | 32.6 | 9.4 |
ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib | 82.4 |
Chlorambucil | 35.3 |
OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | NA |
"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | 18.9 |
The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 45.6 |
Chlorambucil | 20.3 |
In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 84.3 |
Chlorambucil | 45.5 |
The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 27.2 |
Chlorambucil | 11.3 |
In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 77.1 |
Chlorambucil | 42.9 |
Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks
Intervention | ng*h/mL (Geometric Mean) |
---|---|
TDF With a Boosted PI | 3466 |
TAF With a Boosted PI | 743 |
TAF With a Boosted PI and LDV/SOF | 868 |
Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks
Intervention | fmol/2x7mm punches (Geometric Mean) |
---|---|
TDF With a Boosted PI | 36014 |
TAF With a Boosted PI | 6735 |
TAF With a Boosted PI and LDV/SOF | 6100 |
Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks
Intervention | fmol/10^6 cells (Geometric Mean) |
---|---|
TDF With a Boosted PI | 83.0 |
TAF With a Boosted PI | 926 |
TAF With a Boosted PI and LDV/SOF | 1129 |
Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | mL/min/1.73 m^2 (Geometric Mean) |
---|---|
TDF With a Boosted PI | 86.7 |
TAF With a Boosted PI | 91.0 |
TAF With a Boosted PI and LDV/SOF | 88.1 |
Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | mg/g (Geometric Mean) |
---|---|
TDF With a Boosted PI | 134 |
TAF With a Boosted PI | 118 |
TAF With a Boosted PI and LDV/SOF | 97.3 |
Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | ug/g (Geometric Mean) | |
---|---|---|
β2M:Cr ratio | RBP:Cr ratio | |
TAF With a Boosted PI | 224 | 242 |
TAF With a Boosted PI and LDV/SOF | 178 | 146 |
TDF With a Boosted PI | 419 | 436 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib Plus Rituximab | 0 |
The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Intervention | Percentage of Participants (Mean) |
---|---|
Single Arm, Intent to Treat Population | 46 |
1 review available for adenine and Lassitude
Article | Year |
---|---|
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus, | 2018 |
7 trials available for adenine and Lassitude
Article | Year |
---|---|
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl | 2018 |
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2018 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; | 2013 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic | 2017 |
4 other studies available for adenine and Lassitude
Article | Year |
---|---|
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3 | 2022 |
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient S | 2022 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
[Biochemical characteristics of the skeletal muscles of frogs in different stages of fatigue following single stimulations of the nerve].
Topics: Adenine; Adenosine Triphosphate; Coenzymes; Fatigue; Lactates; Muscle, Skeletal; Neuromuscular Junct | 1962 |